Recombinant Cynomolgus CD20 Protein (VLP, Full-length, His Tag)

概述

产品介绍

Cat No. CD20-PC1102

库存：现货

Size

点击咨询在线客服

产品介绍

内毒素

< 1.0 EU per μg protein as determined by the LAL method.

生物活性

1.Immobilized Recombinant Cynomolgus CD20 Protein (VLP, Full-Length, His Tag)(Cat: 90052-C08H1) at 5 μg/mL (100 μL/well) can bind Obinutuzumab derived Anti-CD20 antibody, Human IgG1, the EC₅₀ is 5-20 ng/mL (QC tested).
2.Immobilized Recombinant Cynomolgus CD20 Protein (VLP, Full-Length, His Tag)(Cat: 90052-C08H1) at 5 μg/mL (100 μL/well) can bind Ofatuzumab derived Anti-CD20 antibody, Human IgG1, the EC₅₀ is 10-40 ng/mL (Routinely tested).
3.Immobilized Recombinant Cynomolgus CD20 Protein (VLP, Full-Length, His Tag)(Cat: 90052-C08H1) at 5 μg/mL (100 μL/well) can bind Rituximab derived Anti-CD20 antibody, Human IgG1, the EC₅₀ is 20-60 ng/mL (Routinely tested).

蛋白构建

A DNA sequence encoding the Cynomolgus MS4A1-VLP (Full Length) (M4ZHZ6) (Met1-Pro297) was expressed with a polyhistidine tag at the C-terminus.This protein was prepared using our VLP platform. As an innovative technology platform, VLPs are generated through the self-assembly of viral proteins in HEK293 cells. This process efficiently integrates membrane proteins onto the VLP surface, preserving their native conformation and yielding soluble, high-concentration proteins that are ideally suited for immunization and antibody screening.

表达宿主

HEK293 Cells

种属

Cynomolgus

预测 N 端

Met 1

分子量

The recombinant Cynomolgus MS4A1-VLP consists of 312 amino acids and predicts a molecular mass of 34.73 kDa.

缓冲液

Supplied as sterile 50 mM Hepes, 150 mM NaCl, 10% Trehalose, Protease Inhibitor, pH 7.2.
Please contact us for any concerns or special requirements.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

运输方式

It is supplied and shipped as liquid with dry ice.

稳定性 & 储存条件

Samples are stable for up to twelve months from date of receipt at -70℃. Store it under sterile conditions at -70℃ or lower. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

复溶

To find reconstitution info, click on 'COA' at the top of the page, enter the lot number and product size for the lot-specific COA.

Immobilized Recombinant Cynomolgus CD20 Protein (VLP, Full-Length, His Tag)(Cat: 90052-C08H1) at 5 μg/mL (100 μL/well) can bind Obinutuzumab derived Anti-CD20 antibody, Human IgG1, the EC₅₀ is 5-20 ng/mL (QC tested).

Immobilized Recombinant Cynomolgus CD20 Protein (VLP, Full-Length, His Tag)(Cat: 90052-C08H1) at 5 μg/mL (100 μL/well) can bind Ofatuzumab derived Anti-CD20 antibody, Human IgG1, the EC₅₀ is 10-40 ng/mL (Routinely tested).

Immobilized Recombinant Cynomolgus CD20 Protein (VLP, Full-Length, His Tag)(Cat: 90052-C08H1) at 5 μg/mL (100 μL/well) can bind Rituximab derived Anti-CD20 antibody, Human IgG1, the EC₅₀ is 20-60 ng/mL (Routinely tested).

CD20 背景信息

CD20 (membrane-spanning 4-domains, subfamily A, member 1), also known as MS4A1, is a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. CD20 / MS4A1 is expressed in all stages of B cell development except the first and last. CD20 / MS4A1 is present from pre-pre B cells through memory cells, but not on either pro-B cells or plasma cells. It is a B-lymphocyte surface molecule that plays a role in the development and differentiation of B-cells into plasma cells. CD20 / MS4A1may be involved in the regulation of B-cell activation and proliferation. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5(CVID5). CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections, and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells are usually in the normal range but can be very low.

全称

membrane-spanning 4-domains, subfamily A, member 1

研究领域

Cancer Drug Targets

参考文献

Tedder TF, et al. (1988) Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci. 85(1): 208-12.
Cragg MS, et al. (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 8: 140-74..
Polyak MJ, et al. (2003) A cholesterol-dependent CD20 epitope detected by the FMC7 antibody. Leukemia. 17(7): 1384-9.